A nurse is caring for a client who has diabetes mellitus and is experiencing burning and tingling in their feet. Which of the following medications should the nurse expect to administer?

Diabetic peripheral neuropathy results from chronic hyperglycemia-induced nerve fiber damage and microvascular impairment. The resulting pain is neuropathic rather than nociceptive, requiring medications that modulate neurotransmitter release or stabilize neuronal membranes. Standard analgesics are often ineffective for the characteristic parasthesia and burning sensations associated with this condition. Rationale: A. Gabapentin is an anticonvulsant medication frequently used as a first-line treatment for neuropathic pain. It works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. This stabilization of overactive neurons effectively alleviates the burning and tingling sensations typical of diabetic nerve damage. B. Acetylcysteine is a mucolytic agent used primarily to thin respiratory secretions or as an antidote for acetaminophen toxicity. It does not possess analgesic properties and has no role in managing nerve-related pain. Administering this medication would not address the underlying pathophysiology of the client's peripheral neuropathy or provide any relief for their sensory symptoms in the feet. C. Fentanyl is a potent opioid agonist used for severe, acute, or chronic nociceptive pain. While opioids can mask pain, they are generally not recommended as first-line therapy for diabetic neuropathy due to the high risk of dependence and limited efficacy for neuropathic burning. Treatment guidelines prioritize non-opioid neuromodulators like gabapentin or antidepressants over potent narcotics for this condition. D. Hydromorphone is a strong opioid analgesic indicated for moderate to severe pain that is unresponsive to other treatments. Like fentanyl, it is not the preferred choice for managing the chronic, lancinating pain of diabetic neuropathy. Long-term use of hydromorphone carries a significant risk of tolerance and hyperalgesia without addressing the specific neuronal hyperexcitability that causes the tingling sensations.